Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Advair
Pharma
Novartis calls it quits on Advair generic—and takes a $442M hit
GSK’s respiratory blockbuster Advair was once a top target for generics, but now Novartis is axing its copycat program, to the tune of $442 million.
Eric Sagonowsky
Jan 29, 2020 11:38am
The top 10 all-time biggest-selling drugs by 2024
Aug 15, 2019 11:51am
New respiratory drugs, Shingrix help GSK weather Advair generics
Jul 24, 2019 12:04pm
On a hunt for new revenue, Mylan ponies up $130M for Aspen meds
May 20, 2019 11:45am
GSK chases Trelegy asthma nod with mixed phase 3 results
May 3, 2019 12:10pm
Where's Mylan planning to put its ramped-up 2019 spending?
Feb 27, 2019 10:41am
